| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
GLEN BURNIE, Md.—CavoGene LifeSciences divulged today that it has licensed the rights for the development and commercialization of SynCav1, an investigational gene therapy for patients with neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease (AD), traumatic brain and spinal cord injury, and age-related cognitive decline, from the University of California, San Diego (UC San Diego). SynCav1 is a novel gene therapy intervention that restores and augments pro-growth signaling, axonal and dendritic growth, and formation of new functional synapses in animal models.
 
SynCav1 was developed by Brian P. Head, PhD, a Veterans Affairs’ research scientist and associate adjunct professor in UC San Diego School of Medicine’s Department of Anesthesiology; and co-inventors Hemal H. Patel, PhD, professor and vice-chair for research; Piyush M. Patel, MD, professor; and David M. Roth, MD, PhD, professor. The data demonstrate that SynCav1 improves motor function, maintains body weight and extends survival in ALS rodent models, increases structural and functional neuroplasticity, and improves learning and memory in aged mice and in an AD mouse model.
 
“Cav-1 is a neuronal cell membrane scaffolding protein, analogous to a coat hanger in one’s closet,” said Head. “By recruiting and organizing synaptic receptors and associated signaling components together in close proximity, Cav-1 allows for the enhancement of functional synapses and neuroplasticity. In addition, we believe that this novel gene therapy could also work in combination to enhance the efficacy of compounds that activate synaptic signaling complexes.”
 
SynCav1 represents a new paradigm that uses a single genetic intervention, namely neuron-targeted Caveolin-1 overexpression (e.g., SynCav1), to re-establish polarized plasma membrane signaling microdomains (termed membrane/lipid rafts, MLRs), with improved neurotrophin and synaptic signaling and enhanced neuroregeneration and innervation. Clinically, SynCav1 has the therapeutic potential to improve cognitive function, and to improve the quality of life for those afflicted with neurodegenerative disorders.
 
CavoGene has contracted with CSSi LifeSciences to manage the preclinical, GMP, regulatory and clinical development of SynCav1.
 
Jim Sergi, President of CSSi LifeSciences, stated, “We are excited by the opportunity to leverage our experience and subject matter expertise to advance the commercial development of this potential disease modifying therapy.” 

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue